Isorhapontigenin Inhibits Cell Growth, Angiogenesis, Migration, and Invasion of Non-Small-Cell Lung Cancer Cells Through NEDD9 Signaling
Open Access
- 29 April 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4207
Abstract
Lung cancer is the leading cause of cancer deaths among American men, even though various treatments are available. The discovery and use of new alternative drugs to treat lung cancers are needed to reduce lung cancer mortality. Phytochemicals are potentially desirable therapeutic agents due to their better safety profiles. Isorhapontigenin (ISO) is an orally bioavailable dietary stilbene. Our studies show that treatment with ISO inhibits human lung cancer cell growth, angiogenesis, invasion, and migration. Neural precursor cell expressed developmentally downregulated 9 (NEDD9), a multi-domain scaffolding protein, regulates various processes crucial for tumorigenesis and metastasis. Our results show that NEDD9 is upregulated in the lung tissues from human lung adenocarcinomas (LUADs) and squamous-cell carcinomas (LUSCs) compared to normal lungs. Overexpression of NEDD9 elevates the invasion and migration of human lung cancer cells. Treatment of human lung cancer cells with ISO decreases NEDD9 protein levels. Our studies have also demonstrated that NEDD9 positively regulates angiogenesis, an essential factor in cancer progression. ISO treatment reduces angiogenesis. Moreover, ISO reduces the protein levels of hypoxia-inducible factor-1α (HIF-1α), a transcription factor critical for angiogenesis. Aberrant high expression of β-Catenin leads to various diseases including cancer. Our results show that ISO treatment reduces the activation of β-Catenin through the downregulation of NEDD9. Studies indicate that ISO decreases NEDD9, causing the suppression of cell growth, angiogenesis, invasion, and migration of human lung cancer cells. ISO is a potent therapeutic agent for lung cancer treatment.Keywords
Funding Information
- National Institute of Health (USA) (R01ES030572, R01CA217923, R01CA229234)
This publication has 54 references indexed in Scilit:
- Loss of MEG3 and upregulation of miR-145 play an important role in the invasion and migration of Cr(VI)-transformed cellsHeliyon, 2022
- Exploring flexibility, intermolecular interactions and ADMET profiles of anti-influenza agent isorhapontigenin: A quantum chemical and molecular docking studyHeliyon, 2022
- Isorhapontigenin ameliorates high glucose-induced podocyte and vascular endothelial cell injuries via mitigating oxidative stress and autophagy through the AMPK/Nrf2 pathwayInternational Urology and Nephrology, 2022
- Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cellsCancer Letters, 2021
- Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expressionActa Pharmaceutica Sinica B, 2021
- Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR‐related pathways in prostate cancerJournal of Cellular Physiology, 2017
- Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 CascadeJournal of Investigative Dermatology, 2016
- HIF-1α pathway: role, regulation and intervention for cancer therapyActa Pharmaceutica Sinica B, 2015
- Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseasesGene, 2015
- Regulation of Hypoxia-Inducible Factor-1a by Reactive Oxygen Species : New Developments in an Old DebateJournal of Cellular Biochemistry, 2015